Aquestive Therapeutics (AQST) vs Ovid Therapeutics (OVID)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Ovid Therapeutics (OVID) has outperformed Aquestive Therapeutics (AQST) over the past year, gaining 57.1% versus a loss of 39.5%. Over five years, OVID leads with a -32.5% price change compared with -45.7% for AQST. Aquestive Therapeutics is the larger company by market cap ($434.9 million vs $415.2 million), about 1.0 times the size, while Ovid Therapeutics is growing revenue faster (+1181.3% vs -22.6%).
Aquestive Therapeutics converts more of its revenue into profit, with a net margin of -188.1% versus -240.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AQST | OVID |
|---|---|---|
| Share price | $3.46 | $2.20 |
| Market cap | $434.88M | $415.21M |
| 1-day change | -6.61% | -5.98% |
| YTD return | -46.44% | +34.97% |
| 1-year return | -39.51% | +57.14% |
| 5-year return | -45.68% | -32.52% |
| EPS (TTM) | $-0.65 | $-0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $44.55M | $7.25M |
| Revenue growth (YoY) | -22.61% | +1181.27% |
| Net income (latest FY) | $-83.78M | $-17.41M |
| Gross margin | 58.35% | — |
| Operating margin | -159.50% | -585.20% |
| Net margin | -188.09% | -240.13% |
| 52-week high | $6.74 | $3.11 |
| 52-week low | $2.93 | $1.26 |
| Distance from 52-week high | -48.63% | -29.15% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +169.65% | +179.55% |
| Average volume | 2.41M | 1.98M |
| Shares outstanding | 125.69M | 188.73M |
| Employees | 147 | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OVID has outperformed AQST by 96.7 percentage points over the past year.
- Aquestive Therapeutics is more profitable, keeping -188.1 cents of every revenue dollar as net income versus -240.1 cents for Ovid Therapeutics.
- Ovid Therapeutics grew revenue faster in its latest fiscal year (+1181.27% vs -22.61%).
About Aquestive Therapeutics
AQST stock →Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 147 employees
About Ovid Therapeutics
OVID stock →Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
AQST vs OVID FAQ
Which is bigger, Aquestive Therapeutics or Ovid Therapeutics?
Aquestive Therapeutics (AQST) is larger, with a market capitalization of $434.88M compared with $415.21M for Ovid Therapeutics (OVID).
Which stock has performed better over the past year, AQST or OVID?
OVID returned +57.14% over the past 12 months, compared with -39.51% for AQST (price return, excluding dividends). Past performance does not predict future results.
Are Aquestive Therapeutics and Ovid Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.